Subcutaneous Levodopa Infusion Cuts OFF Time in Real-World Parkinson Care
This systematic review of observational data confirms that continuous subcutaneous levodopa formulations reduce motor fluctuations comparably to trial data, positioning infusion-site management as the central pharmacist responsibility.
New infusion therapy eases Parkinson's motor symptoms with tolerability challenges.
Continuous subcutaneous levodopa infusion offers a promising alternative for managing motor symptoms in advanced Parkinson's disease, potentially improving patient quality of life. The therapy reduced daily OFF time by 2.0 to 3.5 hours and increased quality of life scores by 5.6 to 10.8 points, with infusion-site reactions being the most common adverse events. While effective, the high rate of infusion-site reactions poses a challenge. Comparative and long-term data are needed to further understand safety and efficacy across populations. Subcutaneous infusion of levodopa reduces motor fluctuations but requires monitoring for local reactions.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Ali A, Cheema WA, Shamoon M, Azam H, Yousuf D, Tanveer A, Asif W, Nisar F, Ghafoor LA, Talha M, Ali MA, Saleem U, Shabbir MA, Abdullah A, Sharma M
Citation:Ali A, Cheema WA, Shamoon M, et al. Continuous subcutaneous levodopa and foslevodopa infusion therapy for motor symptoms of Parkinson disease: A systematic review of observational studies. Medicine. 2026;105(27):e49597. doi:10.1097/MD.0000000000049597